近视干预中阿托品滴眼液的临床应用与机制研究进展

Treatment of myopia with low dose atropine eye drops

在全球范围内,近视的患病率逐年上升且呈现出低龄化趋势。如何防控近视以降低其人群发病率,减缓个体病情进展,降低并发症风险,是我国公共健康领域一项亟待攻克的重大课题。药物干预在近视防治中占据着十分重要的地位,其中低浓度阿托品作为一种能够平衡治疗受益和副作用风险的选择,近年来在学界获得关注。本文就其在近视干预中临床应用及作用机制等方面的研究现况与进展做一综述。

With increasing prevalence and high risk of vision-threatening ophthalmic complications,myopia has emerged as a major public health issue worldwide,urging effective interventions to be developed for preventing the progression of myopia.Atropine eye drop at low dosage has been considered as a promising treatment,which could balance the efficacy and safety.This review presents a summary of the clinical use and mechanism study of low dose atropine eye drops in the past few decades.